Tvardi Therapeutics, Inc. (TVRD)
TVRD moved a median of -0.40% 30 minutes after news, and -1.25% by the close. How TVRD actually reacts to news — the realized, point-in-time move the market made, measured across 185 labeled events over the last three years with zero look-ahead.
TVRD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 177 |
| 30-min | -0.40% | 37% | 185 |
| 60-min | -0.59% | 38% | 185 |
| to close | -1.25% | 43% | 183 |
| Middle 50% of TVRD reactions | -1.64% to +1.11% |
|---|---|
| Median reaction (30-min) | -0.40% |
| Measured reactions | 185 |
Half of all Tvardi Therapeutics, Inc. news events land between -1.64% and +1.11% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TVRD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -1.19% | 27% | +0.25% |
| Analyst downgrades | 13 | -2.16% | 15% | +4.17% |
| Coverage initiations | 22 | -0.95% | 27% | +6.57% |
| Rating reiterations | 13 | +0.59% | 69% | +3.25% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how TVRD ranks against every other measured name →
That’s how TVRD usually reacts — get an email when it moves on news →Email me when TVRD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TVRD's baseline. Nothing else.
Recent TVRD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference | Press release | GlobeNewswire | +0.00% | -0.99% | |
| New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC) | Press release | GlobeNewswire | +2.31% | -18.46% | |
| Tvardi Therapeutics to Participate in Upcoming Investor Events | Press release | GlobeNewswire | -1.10% | -2.20% | |
| Form 10-Q Tvardi Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.97% | +4.97% | |
| Form 8-K Tvardi Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +4.97% | +4.97% | |
| Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Press release | GlobeNewswire | +4.97% | +4.97% | |
| Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 | Press release | GlobeNewswire | -1.67% | -1.67% | |
| Form 8-K Tvardi Therapeutics, For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.94% | |
| Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 | Press release | GlobeNewswire | +0.00% | -0.94% | |
| Form 8-K Tvardi Therapeutics, For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | -6.49% | -7.28% | |
| Form 8-K Tvardi Therapeutics, For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | +42.86% | |
| Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement | Press release | GlobeNewswire | -0.86% | +42.86% | |
| Form 8-K Tvardi Therapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.94% | |
| Tvardi Therapeutics to Participate in Upcoming Investor Events | Press release | GlobeNewswire | +0.00% | -6.51% | |
| Form EFFECT Tvardi Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +2.05% | +1.28% | |
| Form EFFECT Tvardi Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.00% | |
| Form 10-Q Tvardi Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.06% | -1.65% | |
| Form 8-K Tvardi Therapeutics, For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -3.06% | -1.65% | |
| Form POS AM Tvardi Therapeutics, | SEC filing · Form POS | SEC EDGAR | +3.54% | +0.25% | |
| Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update | Press release | GlobeNewswire | -3.06% | -1.65% | |
| Form S-3 Tvardi Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +13.46% | |
| Form ARS Tvardi Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.32% | +2.31% | |
| Form DEF 14A Tvardi Therapeutics, For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | +1.32% | +2.31% | |
| Form DEFA14A Tvardi Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +1.32% | +2.31% | |
| Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium | Press release | GlobeNewswire | -1.55% | +4.14% | |
| Form POS EX Tvardi Therapeutics, | SEC filing · Form POS | SEC EDGAR | -3.45% | -4.15% | |
| Form S-8 Tvardi Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -3.45% | -4.15% | |
| Form 10-K Tvardi Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.45% | -4.15% | |
| Form 8-K Tvardi Therapeutics, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -3.45% | -4.15% | |
| Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update | Press release | GlobeNewswire | -3.45% | -4.15% | |
| Form 8-K Tvardi Therapeutics, For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.05% | |
| Tvardi Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | -2.62% | |
| Form 8-K Tvardi Therapeutics, For: Jan 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.33% | |
| Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights | Press release | GlobeNewswire | +3.13% | +8.74% | |
| Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.88% | +7.06% | |
| Form 8-K Tvardi Therapeutics, For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.53% | |
| Form 8-K Tvardi Therapeutics, For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | -2.96% | |
| Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference | Press release | Business Wire | -1.00% | +3.00% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Tvardi Therapeutics, Inc. (TVRD) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.37% | +3.58% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Tvardi Therapeutics, Inc. (TVRD) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +1.12% | +4.49% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Tvardi Therapeutics, Inc. (TVRD) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +1.80% | +3.61% | |
| Tvardi Therapeutics, Inc. (TVRD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.46% | -0.25% | |
| Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Press release | Business Wire | -0.90% | -1.13% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Tvardi Therapeutics, Inc. (TVRD) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -3.40% | -4.25% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.31% | -3.33% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Tvardi Therapeutics, Inc. (TVRD) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -1.89% | -2.31% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Tvardi Therapeutics, Inc. (TVRD) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.00% | -1.87% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Tvardi Therapeutics, Inc. (TVRD) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.00% | +4.28% | |
| Form S-1/A Tvardi Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | -0.49% | -6.24% | |
| Form S-8 Tvardi Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.49% | -6.24% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TVRD section they belong to.
Where else TVRD is measured.
TVRD earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Tvardi Therapeutics, Inc.'s median reaction calculated?
Every labeled TVRD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 185 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of TVRD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TVRD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.